

2024-2025 ECCO Annual Disclosure of Potential Conflict of Interest

Name: Dragoni, Gabriele

In its aim to foster transparency and based on the ICJME Disclosure Form for Potential Conflict of Interest, ECCO has collected the according information of ECCO Officers and invited congress faculty at ECCO'25 via its online submission system.

The CoI Disclosure information is updated every autumn in line with the respective Congress business year. The purpose is to have a comprehensive declaration of interests for ECCO activities.

In case different disclosure answers have been submitted for different ECCO'25 presentations, the 2024-2025 ECCO Annual Disclosure of Potential Conflict of Interest on the association website shows the merged version of the answers to the following questions:

- Disclosure statement:
 - o I have no potential conflict of interest to disclose
 - o I have potential conflict of interest to disclose
- Potential Conflict of Interest can involve: grants, honoraria, shares, paid positions on advisory boards, etc.:
 - o Grant
 - Personal Fees
 - Non-financial support
 - Other

Disclosures statement based on answers received:

Grant: ECCO Grant 2020 ECCO/AOCC Travel Grant 2021 ECCO IIS
Registry Grant 2023 ECCO/IBUS Research Grant 2023 Personal Fees: Speaker's fees from: 2020: Novartis 2022: Janssen 2023: Alfasigma, Janssen, Pfizer, and Takeda 2024: Ferring, Johnson Johnson, Lilly, Pfizer, and Takeda Advisory board fees from: 2023: Celltrion Healthcare and Pfizer 2024: AbbVie